Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the <scp>SURMOUNT</scp> ‐1 to ‐4 trials
In this post hoc analysis, GI AEs appeared to contribute slightly to the weight reduction seen with tirzepatide in participants with obesity or overweight with or without T2D.
Authors
- Sue D. Pedersen (ORCID: https://orcid.org/0000-0002-4355-1764)
- Dachuang Cao (ORCID: https://orcid.org/0000-0003-2291-9037)
- Domenica Rubino (ORCID: https://orcid.org/0000-0002-3072-2819)
- Ryan Griffin (ORCID: https://orcid.org/0009-0003-4071-1181)
- Farai Chigutsa
- Adam Stefański (ORCID: https://orcid.org/0009-0001-7598-402X)
- Claire Gerber
- Lisa Connery
- Julia Fraseur Brumm
Institutions
- Eli Lilly (United States) (US)
- Alliance for Multispecialty Research (United States) (US)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Washington Center for Weight Management and Research (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1111/dom.16176
- Citations
- 12
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 16.73
Funders
- Eli Lilly and Company